• 1
    Chapple CR. Medical therapy and quality of life. Eur Urol 1998; 34 (Suppl. 2): 107.
  • 2
    De Mey C. α1-blockers for BPH: are there differences? Eur Urol 1999; 36: (Suppl. 3): 5263.
  • 3
    Testa R, Sironi G, Colombo D, Greto L, Leonardi A. Rec 15/2739 a new α1-antagonist selective for the lower urinary tract: in vivo studies. Neurourol Urodyn 1994; 13: 4713.
  • 4
    Martin DJ, LLuel P, Guillot E, Coste A, Jammes D, Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 1997; 282: 22835.
  • 5
    Blue DR Jr, Grino P, Jung DT, Harbison MP, Ford ADPW. Evaluation of Ro 70-0004, a selective α1A-adrenoceptor antagonist, in men with benign prostatic hyperplasia (BPH) [abstract]. Proc Fifth International Consultation BPH 2000; 550.
  • 6
    Witte DG, Brune ME, Katwala SP, Milicic I, Stolarik D, Hui YH, Marsh KC, Kerwin JF Jr, Meyer MD, Hancock AA. Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. J Pharmacol Exp Ther 2002; 300: 495504.
  • 7
    Hancock AA, Brune ME, Witte DG, Marsh KC, Katwala S, Milcic I, Ireland LM, Crowell D, Meywr MD, Kerwin JF Jr. Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. J Pharm Exp Ther 1998; 285: 62842.
  • 8
    Michel MC, Büscher R, Kerker J, Kraneis H, Erdbrügger W, Brodde O-E. α1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 38595.
  • 9
    Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288: 2017.
  • 10
    Chapple CR, Roehborn CG. A shifted paradigm for the understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 6519.
  • 11
    Schwinn DA, Roehrborn CG. α1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: 1939.
  • 12
    Roosen A, Chapple CR, Dmchowski RR, Fowler CJ, Gratzke C, Roehborn CG, Stief CG, Andersson K-E. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol 2009; 56: 81020.
  • 13
    Price T, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA. Localization of mRNA for three distinct α1-adrenergic receptor subtypes in human tissues: implications for human α-adrenergic physiology. Mol Pharmacol 1993; 45: 1715.
  • 14
    Andersson KE, Lepor H, Wyllie MG. Prostatic α1-adrenoceptors and uroselectivity. Prostate 1997; 30: 20215.
  • 15
    Michelotti GA, Price DT, Schwinn DA. α1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 2000; 83: 281309.
  • 16
    Stafford-Smith M, Shambra U, Wilson K, Page S, Schwinn DA. α1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic subtypes at four distinct levels. Mol Brain Res 1999; 63: 25461.
  • 17
    Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 31956.
  • 18
    Cavalli A, Lattion A-L, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, Vecchione C, Mostardini M, Schmidt A, Beermann F, Cotecchia S. Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc Natl Acad Sci USA 1997; 94: 1158994.
  • 19
    Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 233643.
  • 20
    Schäfers RF, Fokuhl B, Wasmuth A, Schumacher H, Taguchi K, de Mey C, Philipp T, Michel MC. Differential vascular α1-adrenoceptor antagonism by tamsulosin and terazosin. Br J Clin Pharmacol 1999; 47: 6774.
  • 21
    Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol 1998; 45: 4955.
  • 22
    Sato S, Ohtake A, Matsushima H, Saitoh C, Usuda S, Miyata K. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention contributes to uroselectivity of tamsulosin. J Pharmacol Exp Ther 2001; 296: 697703.
  • 23
    Akiyama K, Hora M, Tatemichi S, Masuda N, Nakamura S, Yamagishi R, Kitazawa M. KMD-3213, a uroselective and long-acting α1a-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999; 291: 8191.
  • 24
    Korstanje C, De Wijn S, Van den Berg S, Swart P. Selective retention of tamsulosin in prostate and bladder and uroselectivity in rat as compared to dog. J Urol 2002; 167: 218.
  • 25
    Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Tsunoo M. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998; 26: 2405.
  • 26
    Qin M, Øie S. Does alpha 1-acid glycoprotein act as a non-functional receptor for alpha 1-adrenergic antagonists? J Pharm Pharmacol 1994; 46: 896901.
  • 27
    Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interaction with drugs. Drug Metab Rev 2001; 33: 161235.
  • 28
    Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJJ, Eichler H-G. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single dose and multiple-dose study. Eur J Clin Pharmacol 1998; 54: 36773.
  • 29
    Rowland M, Tozer TN. Clinical Pharmacokinetics. Media: Williams & Wilkins, 1995; 13755.
  • 30
    Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR. The effects of tamsulosin, a high affinity antagonist at functional α1A- and α1D-adrenoceptor subtypes. Br J Pharmacol 1997; 120: 2318.
  • 31
    Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19 365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998; 160: 78491.
  • 32
    Korstanje C. The improved cardiovascular safety of Omnic (tamsulosin) oral controlled absorption system (OCAS. Eur Urol 2005; 47 (Suppl. 4): 103.
  • 33
    McGrath JC, Lepor H, Wyllie MG. Report of a unique meeting between the alpha-blocker subcommittee and the pharmaceutical industry. Urology 1996; 48: 6657.
  • 34
    Andersson K-E. The concept of uroselectivity. Eur Urol 1998; 33 (Suppl. 2): 711.
  • 35
    Martin DJ, Angel I, Arbilla S. Functional uroselectivity. Eur Urol 1998; 33 (Suppl. 2): 128.
  • 36
    Martin DJ, Lluel P, Pouyet T, Rauch-Desanti C, Angel I. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci 1998; 63: 16976.
  • 37
    Mottet N, Bressolle F, Delmas V, Robert M, Costa P. Prostatic tissue distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003; 44: 1015.
  • 38
    Neill MG, Shahani R, Ziotta AR. Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Ther Clin Risk Manag 2008; 4: 118.